Prescription drug · ANDA
Baclofen NDC 25021-679
Baclofen 2000 ug/mL · Injection, Solution · Intrathecal · Sagent Pharmaceuticals
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 25021-679-20 | 25021067920 | 1 VIAL in 1 CARTON (25021-679-20) / 20 mL in 1 VIALMarketed from Jul 15, 2021 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Baclofen
- Generic name (nonproprietary)
- baclofen
- Active ingredients
- Baclofen — 2000 ug/mL
- Dosage form
- Injection, Solution
- Route
- Intrathecal
- Labeler
- Sagent Pharmaceuticals
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 210048
- Marketing start
- Listing expires
- Other FDA classes
- GABA A Agonists (Mechanism)GABA B Agonists (Mechanism)
- Identifiers
- Product ID 25021-679_9ae563da-240a-468d-bc42-ed4667df2392SPL ID 9ae563da-240a-468d-bc42-ed4667df2392SPL set ID 077aaf3b-1ca3-4599-a51a-6bbe39810ca8RxCUI 308517, 1666613UNII H789N3FKE8
- Pharmacologic class
- gamma-Aminobutyric Acid-ergic Agonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- NDC on a medical claim
N425021067920followed by a unit qualifier and the quantityPackage 25021-0679-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
INDICATIONS AND USAGE Baclofen injection (intrathecal) is indicated for use in the management of severe spasticity. Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion of baclofen injection (intrathecal) via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. Baclofen injec…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 210048
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Baclofen | Baclofen 500 ug/mL | Injection, SolutionIntrathecal | Sagent Pharmaceuticals | 25021-678 |
| Baclofen (Intrathecal)baclofen | Baclofen 500 ug/mL | InjectionIntrathecal | MAIA Pharmaceuticals, Inc. | 70511-122 |
| Baclofen (Intrathecal)baclofen | Baclofen 2000 ug/mL | InjectionIntrathecal | MAIA Pharmaceuticals, Inc. | 70511-124 |